Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 03, 2018 16:05 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals Provides Update on Development Strategy for Avatrombopag in Immune Thrombocytopenic Purpura (ITP) and Chemotherapy-Induced Thrombocytopenia (CIT)

Supplemental NDA for ITP to be submitted in the second half of 2018 Phase 3 Clinical Trial for CIT to begin in the second quarter of 2018 DURHAM, N.C., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Following...
December 04, 2017 16:30 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals Announces Four Presentations at the 59th American Society of Hematology Annual Meeting

DURHAM, N.C., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that the Company will present four abstracts, three of which will be oral presentations, with...
November 27, 2017 16:05 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals Announces FDA Acceptance of the Avatrombopag New Drug Application (NDA) with Priority Review

DURHAM, N.C., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the New Drug Application (NDA) for avatrombopag has been accepted for filing and has been...
November 21, 2017 08:30 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals to Present at Evercore ISI Conference

DURHAM, N.C., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at...
November 10, 2017 08:30 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals to Present at Jefferies 2017 London Healthcare Conference

DURHAM, N.C., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at...
November 09, 2017 16:05 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results

NDA for avatrombopag submitted to FDA Conference call scheduled for 4:30 p.m. EST today DURHAM, N.C., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today reported its...
November 02, 2017 16:30 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 9, 2017

DURHAM, N.C., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare...
October 10, 2017 16:30 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals to Present Phase 3 Avatrombopag Data at the 2017 Liver Meeting of the American Association for the Study of Liver Diseases (AASLD)

Detailed Safety and Efficacy Results from ADAPT-1 and ADAPT-2 Phase 3 Trials to be Reported in Oral Presentation Company to Host Investor and Analyst Conference Call and Webcast at 5:00 p.m. on...
September 22, 2017 07:00 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals Announces New Drug Application Submission to FDA for Avatrombopag, a Second Generation Thrombopoietin Receptor Agonist

DURHAM, N.C., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a specialty pharmaceutical company, today announced the submission of a New Drug Application (NDA) to the...
September 20, 2017 16:15 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals to Present at 2017 Leerink Partners Rare Disease Roundtable

DURHAM, N.C., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at...